Abraxane Gains Indication for First-Line NSCLC Therapy

Share this content:

Celgene announced that the FDA has approved Abraxane (nanoparticle albumin bound [nab]-paclitaxel for injectable suspension) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

The approval of supplemental New Drug Application (sNDA) is based on the results of a CA-031, a Phase 3, multi-center randomized open-label study where patients with NSCLC received either Abraxane (100mg/m2) weekly plus carboplatin (AUC=6) every three weeks or paclitaxel (200mg/m2) every three weeks plus carboplatin (AUC=6). The study met its primary endpoint demonstrating a statistically significantly higher overall response rate in the Abraxane arm compared to those in the paclitaxel arm (33% vs. 25%).

Abraxane, a taxane antimicrotubule agent, was first approved in 2005 for the treatment of metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.

For more information call (908) 679-9000 or visit www.abraxane.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs